The drugs include Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets and the company is the exclusive first-to-file for this products ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Ozempic can cause bone density loss and I didn't think that would happen to me because I was only on it for a year. But I ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.